EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?
9/26/2024
0:00
49:56
This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:
- Compares traditional ultrasound with advanced imaging techniques.
- Examines AI-based approaches in patient classification.
The episode concludes with a forward-looking perspective on the future management of MASLD.
Faculty
- Thomas Berg (Moderator)
- Timm Denecke (Faculty)
- Juan-Manuel Pericàs (Faculty)
- Valérie Vilgrain (Faculty)
This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.
Related episodes
- EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
- EASL Studio S6E1: Do we solve MASLD by treating obesity?
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
All EASL Studio Podcasts are available on EASL Campus.
More episodes from "EASL Podcasts"
Don't miss an episode of “EASL Podcasts” and subscribe to it in the GetPodcast app.
